Clinical Report: Evaluation of Growth Hormone Treatment Following Pediatric HCT
Overview
This study evaluates the effectiveness of growth hormone (GH) therapy in pediatric hematopoietic cell transplantation (HCT) survivors with short stature. GH therapy was associated with significant improvements in height outcomes, although responses varied based on clinical factors.
Background
Growth impairment is a significant late effect in survivors of childhood HCT, impacting long-term quality of life. GH deficiency is common in this population, particularly among those exposed to total body irradiation and other intensive treatments. Understanding the effectiveness of GH therapy is crucial for optimizing growth outcomes in these patients.
Data Highlights
Parameter
GH Therapy
No GH Therapy
Final Height SDS Improvement
Significant
Less Improvement
ΔSDS
Greater
Lower
Patients Treated
58
113
Key Findings
GH therapy significantly improved final height SDS and ΔSDS in treated patients.
Height outcomes were poorer in patients who received total body irradiation (TBI) and those with chronic graft-versus-host disease.
Factors influencing GH responsiveness included absence of TBI and female sex in allogeneic HCT patients.
GH therapy did not increase the risk of slipped capital femoral epiphysis, secondary malignancies, or disease relapse.
Long-term response patterns to GH therapy were heterogeneous among patients.
Clinical Implications
Clinicians should consider GH therapy for pediatric HCT survivors with short stature, while being aware of the variability in response based on individual clinical factors. Ongoing monitoring and tailored strategies may be necessary to optimize growth outcomes.
Conclusion
GH therapy can enhance height outcomes in pediatric HCT survivors, but responses are influenced by transplant-related factors. Further research is needed to refine treatment approaches for those at risk of poor response.
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
